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Key Points
•Using EBMT data in
.2000 patients from
1994 to 2015, we ana-
lyzed the development
and factors influencing
outcomes of HSCT for
ADs.
• Transplant center ex-
perience, accreditation,
and national socioeco-
nomic factors are rele-
vant for outcomes and
future health service
delivery.
Hematopoietic stem cell transplantation (HSCT) has evolved for.20 years as a speciﬁc treatment
of patients with autoimmune disease (AD). Using European Society for Blood and Marrow
Transplantation registry data, we summarized trends and identiﬁed factors inﬂuencing activity
and outcomes in patients with AD undergoing ﬁrst autologous HSCT (n 5 1951; median age, 37
years [3-76]) and allogeneic HSCT (n 5 105; median age, 12 years [,1-62]) in 247 centers in 40
countries from 1994 to 2015. Predominant countries of activity were Italy, Germany, Sweden, the
United Kingdom, The Netherlands, Spain, France, and Australia. National activity correlated with
the Human Development Index (P 5 .006). For autologous HSCT, outcomes varied signiﬁcantly
between diseases. There was chronological improvement in progression-free survival (PFS,
P , 1025), relapse/progression (P , 1025), and nonrelapse mortality (P 5 .01). Health care
expenditure was associated with improved outcomes in systemic sclerosis and multiple sclerosis
(MS). On multivariate analysis selecting adults for MS, systemic sclerosis, and Crohn disease,
better PFSwas associatedwith experience ($23 transplants for AD, P5 .001), learning (time from
ﬁrst HSCT for AD $6 years, P 5 .01), and Joint Accreditation Committee of the International
Society for Cellular Therapy and European Society for Blood and Marrow Transplantation
accreditation status (P 5 .02). Despite improved survival over time (P 5 .02), allogeneic
HSCT use remained low and largely restricted to pediatric practice. Autologous HSCT has
evolved into a treatment modality to be considered alongside other modern therapies in
severe AD. Center experience, accreditation, interspecialty networking, and national
socioeconomic factors are relevant for health service delivery of HSCT in AD.
Submitted 29 June 2017; accepted 27 October 2017. DOI 10.1182/
bloodadvances.2017010041.
The full-text version of this article contains a data supplement.
© 2017 by The American Society of Hematology
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Introduction
Autoimmune diseases (ADs) affect;8% of the population in Western
countries, but not all are severe and most respond to standard
immunosuppressive treatments and supportive care. However, cure
remains elusive andmany patients suffer the chronic effects of both the
disease and their treatment. Economic costs are not only associated
with pharmaceuticals, but also with considerable personal and societal
impact, especially in progressively disabling states.
Supported originally by preclinical studies and serendipitous
case reports, hematopoietic stem cell transplantation (HSCT) has
been evolving as a specific treatment of patients with ADs
responding poorly or refractory to conventional treatments.1-4 In
the mid-1990s, the first transplants performed specifically for
ADs were followed by the formation of the European Society for
Blood and Marrow Transplantation (EBMT) Autoimmune Dis-
eases Working Party (ADWP) in 1997. The EBMT database was
established and multidisciplinary recommendations were pub-
lished to advise on selection and management of patients5;
these have been updated by the EBMT.6,7 Similar developments
happened worldwide and there have been a large number of
retrospective and prospective studies in a wide range of ADs.8-27
More recently, randomized controlled trials have reported con-
firming proof of principle in several ADs.28-32 Despite international
guidelines and recommendations, the uptake of HSCT in AD has
been highly variable, both geographically and in respect to type of
AD. Factors operational in this relatively specialized area of HSCT
practice are unclear, and there have been only 2 national analyses
to date that showed different uptake to each other and the overall
EBMT picture.33,34
The EBMT ADWP database has now accumulated.2000 patients
dating back over 20 years. The aim of this retrospective analysis
was to use the EBMT database to summarize the evolution and
trends in the development of HSCT for ADs in Europe and other
partner countries outside of Europe. In addition, we aimed to identify
factors that influence activity and outcomes, including center
experience, accreditation status, and health economics, which have
been recently linked with improved outcomes in more general
analyses of HSCT.35
Patients and methods
EBMT Registry
The EBMT is a not-for-profit, scientific society representing .600
HSCT centers in Europe and other regions of the world. The
mission of the EBMT includes quality improvement supported by
the central registration of activity relating to HSCT; since 1986,
there have beenmore than half a million registrations. Data are entered,
managed, and maintained in a central database in accordance with
legal and regulatory requirements for patient consent, data
protection, confidentiality, and accuracy. Quality assurance mea-
sures include several independent systems: confirmation of validity
of the entered data by the reporting team, annual survey exercises,
cross-checking with national registries, and regular in-house and
external data audits, which are underpinned by accreditation
exercises. All EBMT teams are required to obtain signed informed
consent for transfer of anonymized data via standardized generic and
disease-specific EBMT minimal essential data forms in accordance
with data protection regulations. Per EBMT procedures, this study
was approved by the ADWP and selected patients who had received
HSCT for an AD since the first registration in 1994.
Since 1994, 247 centers in 40 countries have reported data
relating to HSCT in AD. Total transplants were recorded as first,
second, or third. Teams were predominantly European and are
listed in the supplemental Appendix in alphabetical order by country,
city, and EBMT center code. Data composing 8% of the total
dataset and submitted by centers in the following 10 non-European
countries (based on World Health Organization criteria [www.who.
org]) were included in the analyses: Australia, Brazil, Canada,
China, Colombia, Jordan, Lebanon, Saudi Arabia, Singapore, and
South Africa. To adjust for population, transplant rates per country
were also calculated as numbers of first HSCT per million
inhabitants. National populations were obtained from Eurostat
(http://ec.europa.eu/eurostat/data/database) except for Australia,
which was the only non-European country included in this part of
the analysis. Patients (112, 5.3%) who had been enrolled on the
prospective EBMT-based randomized clinical trials Autologous
Stem Cell Transplantation International Scleroderma (ASTIS),29
Autologous Hematopoietic Stem Cell Transplantation In Multiple
Sclerosis (ASTIMS),30 and Autologous Stem Cell Transplantation
for Crohn’s Disease (ASTIC)31 were included in the demographic
analyses but excluded from the long-term outcomes analyses.
The impact of accreditation by the Joint Accreditation Committee of
the International Society for Cellular Therapy and EBMT (JACIE),
which awarded its first accreditation in 2001,36 was investigated
according to transplants being performed in centers before or
without JACIE accreditation vs after JACIE accreditation, based on
the date of JACIE accreditation being awarded (data source: JACIE
Office, Barcelona, Spain).
Analysis was also performed to explore the association of recent
HSCT activity for AD with socioeconomic and macroeconomic
factors as well as the organization of transplant teams in European
countries. For this purpose the number of autologous HSCTs
performed between 2010 and 2015 standardized for country
population was correlated with the Human Development Index
(HDI), current health care expenditure (HCE), and team density
(ie, the number of transplant teams divided by population). The HDI
is commissioned by the United Nations Organization to evaluate a
country’s socioeconomic achievements in 3 basic aspects:
longevity, knowledge, and standard of living. Values of HDI were
obtained from the 2013 Human Development Report (http://hdr.
undp.org/sites/default/files/reports/14/hdr2013_en_complete.
pdf). HCE is defined as the total annual consumption of health goods
and services plus capital investment in health care infrastructure,
standardized per country population. It includes spending by both
public and private sources. Data on HCE were obtained from the
Eurostat (http://appsso.eurostat.ec.europa.eu) for the year 2012.
Only countries that reported at least 1 HSCT for an AD in the study
period were included in the analysis. Data on HCE were available for
18 of 23 countries. For the most frequent indications (multiple
sclerosis [MS], systemic sclerosis [SSc], Crohn disease [CD])
results of autologous HSCT were analyzed with respect to median
HDI, HCE, and team density of included countries.
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Statistical analysis
Descriptive statistics and graphical display were used to summarize
trends in HSCT activity over time, per indication and nationally.
For survival analysis, the primary end points were progression-free
survival (PFS), relapse incidence (RI), nonrelapse mortality (NRM),
and overall survival (OS). PFS was defined as survival with no
evidence of relapse or progression; RI as either relapse or progres-
sion; NRM as death without evidence of relapse or progression; and
OS as the time from transplantation to death, regardless of the cause.
Cumulative incidence functions were used to estimate RI and NRM in
a competing risks setting because death and relapse compete with
each other. Probabilities of PFS and OS were calculated using
Kaplan-Meier estimates. Univariate analyses were performed using
the Gray test for cumulative incidence functions and the log-rank
test for PFS and OS. The influence of chronological timing of transplant
on OS, PFS, RI, and NRM in 5-year “epochs” (ie, 1995-1999,
2000-2004, 2005-2010, and 2011-2015) were analyzed for MS, SSc,
and CD. To investigate the impact of center activity, transplant activity
was dichotomized around the median into low (,23 HSCT) and high
($23 HSCT) for autologous HSCT procedures. The impact of overall
center experience was also investigated by year of original EBMT
center registration for first transplant procedure for AD. Small numbers
prevented comprehensive analyses in the allogeneic HSCT group.
Associations of patient and graft characteristics with outcomes
were evaluated in adult patients autografted for the 3 main
indications (MS, SSc, and CD) by multivariate analysis using Cox
proportional hazards model. All tests were 2-sided. The type 1 error
rate was fixed at 0.05 for determination of factors associated with time
to event outcomes. Spearman R test was used to evaluate the health
economic associations. Statistical analyses were performed with
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Figure 1. Trends in activity for HSCT in autoimmune
diseases. (A) By autologous and allogeneic HSCT and (B) by
indication. IDD, insulin-dependent diabetes.
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Figure 2. Trends in activity of autologous HSCT. (A) MS
overall, (B) ratio of relapsing remitting (RR)–MS to progressive
MS, (C) systemic sclerosis, (D) Crohn disease, (E) SLE, and
(F) inflammatory arthritis.
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SPSS 22 (SPSS Inc./IBM, Armonk, NY) and R 3.2.3 (R Development
Core Team, Vienna, Austria) software packages.
Results
Registrations and activity
Between January 1994 and December 2015, there were 2097
transplant procedures in 2056 patients (62% female, 8% pediatric
,18 years) registered by 247 participating centers in 40 countries.
Among 2097 HSCT procedures, there were 1951 patients un-
dergoing first autologous HSCT, with a median age of 37 years
(3-76), and 105 patients (11%) undergoing allogeneic HSCT, with a
median age of 12 years (,1-62). Forty-one patients had undergone
second or third HSCT procedures. Of the 247 teams, most (75%)
restricted their activity to autologous HSCT only, but 48 teams (19%)
registered both autologous and allogeneic HSCT and 15 teams (6%)
registered allogeneic HSCT only. A total of 112 (5.4%) patients were
treated on the EBMT ASTIS, ASTIMS, and ASTIC trials.
Transplant activity in total and for individual ADs is summarized in
Figures 1 and 2. The main indications based on patients treated
were MS (n 5 839), connective tissue disorders (n 5 596),
inflammatory arthritis (IA, n5 178), vasculitis (n5 46), inflammatory
bowel disease (In5 191), hematological immune cytopenia (n5 97),
and IDD (n 5 20). Eighty-one patients were treated for other
neurological diseases including chronic inflammatory demyelin-
ating polyneuropathy (n 5 34), neuromyelitis optica (n 5 19),
and myasthenia gravis (n 5 7). There were 2 peaks of activity,
initially in 1999, when IA was the most common indication, then a
gradual upward trend from 2006 to 2015, with MS, SSc, and
CD, and for which EBMT-based randomized controlled trials had
been available, became the most common indications. Annual
overall numbers have been increasing in recent years, particu-
larly with MS and SSc, whereas other indications, such as IA
and systemic lupus erythematosus (SLE), have diminished
considerably.
National activity
Transplant rates differed substantially among participating European
countries. The predominant countries of activity were Italy, Germany,
Sweden, the United Kingdom, The Netherlands, Spain, France, and
Australia (Figure 3A), which made up 74% of the activity, although
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Figure 3. Trends in the activity of HSCT in AD by nation.
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some other smaller countries contributed highly based on per head of
population (Figure 3B). There was considerable variation in case mix
between countries (Figure 3A).
In the 2010 to 2015 period, the national transplant rates for
autologous HSCT correlated with the values of HDI (Spearman
R 5 0.55, P 5 .006). No significant associations were found
between the transplant rates and HCE (Spearman R5 0.31, P5 .21)
or team density per population (Spearman R 5 0.28, P 5 .2).
Outcomes of autologous HSCT and
influencing factors
Outcome analysis of the patients undergoing first autologous
HSCT, based on 827 for MS, 379 for SSc, 115 for CD, 107 for
SLE, 75 for rheumatoid arthritis, 75 for juvenile idiopathic arthritis,
39 for vasculitis, 42 for hematological immune cytopenias, 20 for
IDD, and 160 for other indications with a median follow-up of 34
(,1-234) months), showed global 3- and 5-year OS rates of 89%
and 86%, PFS of 57% and 49%, RI of 38% and 46%, and NRM of
4.6% and 5.3%.
Outcome according to time periods. On univariate anal-
ysis of outcomes across time epochs (1994-1999, 2000-2004,
2005-2010, and 2011-2015), there was a chronological improve-
ment in PFS (P , 1025), relapse/progression (P , 1025), and
NRM (P 5 .01) (Figure 4).
Outcome according to economic factors. On univariate
analysis restricted to autologous HSCT in patients with MS, HCE
greater than the median was associated with increased probability of
PFS (P 5 .02) whereas national team density per population greater
than the median was associated with reduced RI (P 5 .002) and
increased rate of PFS (P5 .004). Among patients with SSc, increased
probability of OS (P 5 .01) and decreased incidence of both early
(P5 .02) and overall NRM (P5 .02) was observed for countries with
HCE greater than the median. No associations of outcome with
socioeconomic factors and team density were observed for patients
with CD, perhaps because of limited numbers (Table 1).
Prognostic factors after autologous HSCT. Outcomes
(NRM, relapse/progression, PFS, and OS) varied significantly
among the 3 most common current indications (ie, MS, SSc,
and CD) and are presented graphically in Figure 5. This was
confirmed in multivariate analysis of adult patients (Table 2). Other
factors independently associated with a better PFS were
experience ($23 transplants for AD, P 5 .001), learning (time
from first HSCT for AD $6 years, P 5 .01), and JACIE
accreditation status (P 5 .02). There was also a very strong
influence of age, with significantly lower NRM and better survival in
younger patients.
Trends in autologous transplant techniques. With re-
spect to stem cell source, there was a significant trend to increasing
use of peripheral blood stem cell (1994-1999, 86.3%; 2000-2004,
92.9%, 2005-2010, 98.2%; and 2011-2015, 99.6%; P , 1023).
Trends in conditioning regimens, subgrouped per previous EBMT
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guidelines6 (ie, (a) “high intensity,” including total body irradiation or
high-dose busulphan-containing regimens, (b) “low intensity,”
referring to cytarabine alone, melphalan alone, and fludarabine-
based regimens, or (c) “intermediate intensity,” including other
combinations, such as carmustine, etoposide, cytarabine, and
melphalan, and, in most patients, the combined use of antithymo-
cyte globulin with high-dose cytarabine or other chemotherapy)
confirmed significant changes in the intensity of the conditioning
regimens used for autologous HSCT over the 4 time epochs, with
an increasing use of intermediate intensity regimens in the 3 main
indications, MS (P , 1023), SSc (P , 1023), and CD (P 5 .02).
Overall, the improvements in outcomes across the time epochs
were statistically stronger for patients treated with intermediate
intensity regimens (Table 3).
Table 1. Results of autologous hematopoietic stem cell transplantation according to country socioeconomic factors and transplant team
density
N RI, % (95% CI) NRM, % (95% CI) 100 d NRM, % (95% CI) PFS, % (95% CI) OS, % (95% CI)
Multiple sclerosis
HDI
#Median 503 35.4 (29.9-40.9) 1.6 (0.7-3.2) 1.6 (0.7-3.2) 63 (57.4-68.6) 95.4 (93.3-97.6)
.Median 226 38.5 (29.5-47.3) 0.5 (0-2.6) 0.5 (0-2.6) 61 (52.1-69.9) 95.5 (91.8-99.3)
P .98 .55 .55 .87 .27
HCE
#Median 291 46.1 (38.3-53.6) 2 (0.8-4.5) 2.1 (0.8-4.5) 51.8 (44.2-59.5) 94.8 (91.7-97.9)
.Median 205 37.9 (28.5-47.3) 0 0 62.1 (52.6-71.6) 95.5 (91.4-99.7)
P .054 .21 .2 .02 .59
Team density
#Median 465 42.6 (36.2-48.9) 1 (0.3-2.4) 1 (0.3-2.4) 56.4 (50-62.8) 96.4 (94.3-98.5)
.Median 264 27.5 (21-34.4) 1.8 (0.6-4.2) 1.8 (0.6-4.2) 70.7 (63.9-77.6) 94.1 (90.8-97.5)
P .002 .63 .66 .004 .24
Systemic sclerosis
HDI
#Median 124 31 (21.6-40.8) 10 (5-16.9) 6.4 (2.8-12.1) 59 (48.8-69.3) 79.1 (70.7-87.5)
.Median 209 31.1 (23.8-38.7) 7 (3.9-11.2) 5.2 (2.7-9) 6 1.9 (54.1-69.7) 81.1 (75.3-87)
P .8 .44 .44 .8 .4
HCE
#Median 117 37.3 (27.1-47.5) 11.8 (6.4-19.1) 8.4 (4.1-14.6) 50.9 (40.3-61.5) 75.2 (66.4-84)
.Median 154 29.3 (20.9-38.1) 5.8 (2.7-10.7) 4.2 (1.7-8.5) 64.9 (55.9-73.9) 81.5 (74.6-88.5)
P .71 .02 .02 .07 .01
Team density
#Median 123 30.1 (20.8-40) 9 (4.3-15.7) 6.4 (2.8-12.1) 60.9 (50.6-71.2) 80.5 (72.3-88.6)
.Median 210 31.6 (24.2-39.2) 7.5 (4.3-11.9) 5.2 (2.6-9) 60.9 (53.1-68.7) 80.4 (74.5-86.4)
P .87 .79 .77 .75 .93
Crohn disease
HDI
#Median 60 62.8 (45.4-76.1) 1.7 (0.1-8.2) 1.7 (0.1-8.2) 35.5 (20.5-50.4) 98.3 (95-100)
.Median 41 56.5 (31.3-75.6) 0 0 43.5 (21.7-65.4) 97.5 (92.7-100)
P .31 .44 .44 .23 .87
HCE
#Median 46 60.5 (41-75.3) 2.2 (0.2-10.1) 2.2 (0.2-10.1) 37.3 (20.6-54.1) 97.8 (93.6-100)
.Median 41 56.5 (31.3-75.6) 0 0 43.5 (21.7-65.4) 97.5 (92.7-100)
P .45 .38 .38 .33 .9
Team density
#Median 56 57.8 (40.5-71.8) 1.8 (0.1-8.6) 1.8 (0.1-8.6) 40.3 (24.9-55.8) 96.4 (91.6-100)
.Median 45 65.6 (39.5-82.5) 0 0 34.4 (13.8-55.1) 100 (100-100)
P .76 .41 .41 .61 .7
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Outcomes of allogeneic HSCT
Long-term outcome analysis of the patients undergoing first
allogeneic HSCT showed global 3- and 5-year OS rates of 67%
and 64%, PFS 59% and 56%, and RI 21% and 24%, respectively.
NRM rose from 13% at 100 days and plateaued at 20% at 3 and 5
years. Only univariate analysis was possible because of limited
numbers. There was evidence for improvement of OS over the time
epochs (2000-2004, 2005-2010, and 2011-2015), better out-
comes in patients ,18 years in terms of relapse (P 5 .002), but no
effect of center experience ($2 patients). Detailed analysis of
indications was limited by data, although OS was better in arthritis
than hematological immune cytopenia (P 5 .03).
Discussion
This extended report using the EBMT registry confirms that activity in
HSCT for severe AD is sustained and increasing, despite the
introduction andwidespread adoption of biological and other modern
therapies in neurology, rheumatology, gastroenterology, and other
specialties. The doubling of activity of autologous HSCT procedures
between 2011 and 2015 supports the impact of publishing EBMT
guidelines6 and of the EBMT ASTIS, ASTIMS, and ASTIC trials,29-31
along with other higher quality data in MS, SSc, and CD.
For the past 15 years, MS has emerged as the major indication, and
with the increased evidence base supporting the greatest benefit in
the inflammatory phase of disease,37,38 there has been a gradual shift
to a major predominance of relapsing-remitting over progressive
forms. Despite the relatively high risks of HSCT in SSc, the increasing
activity is now supported by 3 randomized controlled trials providing
proof of principle over conventional treatment.26,29,32 Contrastingly,
in other diseases, particularly IA and SLE, in which biological and
other modern therapy has proven highly effective and well tolerated,
activity of autologous HSCT has fallen dramatically despite evidence
of benefit.8,10,13
Activity has varied considerably between countries, both overall
and per head of population, and in relation to specific ADs. The
reasons for this are not clear but potentially explained by the
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Figure 5. Long-term OS, PFS, cumulative relapse incidence, and NRM following first autologous HSCT in MS, SSc, and CD. Data for 100-day NRM and 3-year
NRM, RI, PFS, and OS for each disease were as follows: MS, 1.1% (95% CI, 0.5-2.1) and 1.5% (95% CI, 0.8-2.7), 34.4% (95% CI, 30.1-38.8), 64% (95% CI, 59.6-68.5),
and 95.5% (95% CI, 0.80-2.7); SSc, 5% (95% CI, 3.7-7.7), 7.2% (95% CI, 4.7-10.4), 31.1% (95% CI, 25.5-36.7), 61.8% (95% CI, 55.9-67.6), and 80.3% (95% CI, 75.8-
84.8); CD, 0.9% (95% CI, 0.1-4.7), 0.9% (95% CI, 0.1-4.7), 60.4% (95% CI, 47.7-70.9), 38.7% (95% CI, 27.2-50.1), and 96.7% (95% CI, 93-100).
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relationship between HSCT and disease-specific societies at
the national level and other local working partnerships. On a more
general level, our analysis supports national activity being related to
the socioeconomic status of a country, as reflected by the HDI. This is
consistent with previous analyses relating to acute leukemias and
general HSCT activity.39,40 However, in contrast to previous reports
covering HSCT as a whole, we were unable to demonstrate a
significant correlation between transplant rates in European countries
and HCE or team density.40,41Our results suggest that some factors
specific to autoimmune diseases may be relevant, such as uptake of
HSCT as a potential treatment by disease-specific national societies
and communities and health service funding of transplant procedures.
As demonstrated for other diseases, economic factors may influence
outcome.41,42 According to results of our univariate analysis for
patients with MS and SSc, autologous HSCT performed in countries
with lower HCEwas associatedwith increased risk of NRMand inferior
PFS rates. Such association of economic factors with outcome in the
field of autoimmune diseases requires further investigation.
In support of a learning and experiential curve, there was
significant improvement in NRM along with PFS and relapse rate
in the epoch analysis. The benefit of center experience is also
reflected by improved outcomes in more active centers ($23) and
those with a longer history of performing HSCT for ADs. JACIE
accreditation was associated with better PFS and lower relapse
rates, supporting better patient selection or other unidentified
factors. Refinement of autologous transplant technique with time,
with increasing use of peripheral blood stem cell and “intermedi-
ate” intensity conditioning regimens (as per current EBMT
guidelines6) may have contributed, although it was not possible
to quantitate the impact of improved supportive care over the past
2 decades using the EBMT registry.
Another major influence is the type of autoimmune disease being
transplanted, with significant differences in outcomes among MS,
SSc, and CD. NRM at 100 days was markedly different, especially in
the major AD indications. In MS and CD, it was significantly lower than
with SSc (in which there is often compromise of vital organ function
resulting in poor tolerance of HSCT). To improve NRM risk in SSc, the
Table 2.Relationship among age, year of HSCT, JACIE accreditation status, mean center size, and outcome of autologous HSCT for AD using
multivariate Cox analysis
Relapse HR (95% CI) NRM HR (95% CI) NRM day 100 HR (95% CI) PFS HR (95% CI) OS HR (95% CI)
Age (at transplant)
per 10-y period
1.00 (0.90-1.11) 1.51 (1.14-2.02) 1.73 (1.17-2.55) 1.05 (0.95-1.16) 1.35 (1.15-1.58)
P .97 .005 .006 .32 .0002
MS (reference) 1 1 1 1 1
SSc 0.9 (0.70-1.16) 3.10 (1.50-6.41) 3.05 (1.21-7.70) 1.04 (0.83-1.31) 3.18 (2.18-4.66)
P .41 .002 .018 .72 ,1025
CD 2.42 (1.73-3.39) 0.82 (0.11-6.36) 1.08 (0.13-8.80) 2.32 (1.67-3.22) 0.68 (0.21-2.21)
P ,1025 .85 .94 ,1025 .53
$23 autologous HSCT
for AD (experience)
0.77 (0.62-0.95) 0.36 (0.18-0.73) 0.29 (0.11-0.74) 0.72 (0.59-0.88) 0.62 (0.44-0.88)
P .017 .004 .010 .001 .007
$6 y from first HSCT
for AD (learning)
0.78 (0.60-0.97) 0.55 (0.26-1.16) 0.35 (0.14-0.89) 0.74 (0.59-0.93) 0.89 (0.59-1.34)
P .02 .12 .028 .010 .58
After JACIE 0.70 (0.50-0.98) 0.37 (0.11-1.27) 0.55 (0.15-1.94) 0.67 (0.49-0.93) 0.59 (0.33-1.08)
P .04 .12 .35 .015 .087
$42 autos/y for any indication
(mean center size)
1.03 (0.84-1.27) 0.95 (0.50-1.80) 1.26 (0.56-2.85) 1.03 (0.85-1.26) 0.90 (0.64-1.27)
P .76 .88 .58 .76 .54
Hazard ratio (HR) ,1 5 good prognosis.
Autos, autologous HSCTs.
Table 3. Improvement with 3-y outcomes over time epochs in patients undergoing first autologous HSCT with intermediate intensity
conditioning regimens
N RI/progression, % (95% CI) NRM, % (95% CI) 100-d NRM, % (95% CI) PFS, % (95% CI) OS, % (95% CI)
1995-1999 140 42.8 (34.4-50.9) 7.2 (3.7-12.3) 7.2 (3.7-12.3) 50 (41.7-58.4) 85.6 (79.8-91.5)
2000-2004 199 37.3 (30.4-44.2) 5.8 (3.1-9.7) 4.7 (2.3-8.4) 56.9 (49.8-64) 88.1 (83.6-92.7)
2005-2010 470 29.1 (24.6-33.8) 4.9 (3.1-7.3) 3.9 (2.4-6.1) 65.9 (61.1-70.7) 89.1 (86.1-92.1)
2011-2015 650 33.8 (27.3-40.4) 1.4 (0.6-2.8) 1.2 (0.5-2.4) 64.8 (58.2-71.4) 93.6 (90.7-96.6)
P .001 .002 .002 ,105 .006
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ADWP has recently published recommendations for cardiopulmonary
screening as a means of optimizing patient selection.7
The use of allogeneic HSCT remained low throughout the whole
period and is largely restricted to pediatric practice, with hematolog-
ical immune cytopenias as the predominant indication. Unfortunately,
the limited numbers prevented detailed analyses of trends and
outcomes, although long-term survival outcomes support basic
biological differences in the responses of AD to allogeneic and
autologous HSCT in terms of cure, with long-term NRM risks of
;20%, allogeneic HSCT will remain limited and developmental in its
application to ADs. Further research using registry data is needed.
We recognize that there are limitations to this type of registry-based
analysis, which covers many types of AD. For example, we accept
limitations in the recording of responses of individual AD compared
with specially designed prospective trials in specific AD. In the current
EBMT Guidelines,6 we have highlighted the challenge of applying
the usual, mainly oncology-based, response parameters in HSCT
(ie, complete response, partial response, relapse/progression, and
NRM with associated OS and PFS to AD), where various “bespoke”
classifications have been used and there is conventionally a much
greater emphasis is on functional and quality of life responses than in
oncology. However, in a large aggregated retrospective analysis of this
kind, the use of standard HSCT response parameters provides the
opportunity for a broad assessment of the impact of HSCT in patients
with severe treatment-resistant AD, most of whom were treated on an
individualized compassionate basis outside of large clinical trials.
The future of HSCT in autoimmune diseases very much depends on the
“dynamic”with alternative treatment options, including the new biological
agents. Ongoing development of the field depends on hematologists
working closely with other specialists and their respective societies, as
well as public health commissioners, to define where HSCT sits in
relation to other modern treatments. Even in MS, SSc, and CD, the
evidence base for HSCT is still relatively limited, and further prospective
studies are required to compareHSCTwith evolvingmodern treatments.
Studies are also required to refine conditioning regimens and other
aspects of care, which were originally translated from oncological or
aplastic anemia practice and agreed by consensus rather than design.43
Late effects of HSCT and nontransplant treatments also need to be
considered, including impacts on the endocrine, reproductive, and
cardiovascular systems as well as secondary autoimmune diseases
and neoplasia.6,44-46
In conjunction with both prospective and registry studies, mecha-
nistic studies have been progressively produced.47-50 The recent
publication of guidelines for studies of immune reconstitution
studies and biobanking provides the necessary framework for
further development of mechanistic studies.51 More standardized
approaches to immune monitoring should facilitate correlative
studies with outcomes of HSCT and potentially enable biomarkers
to be developed to assist with patient selection and treatments.52
As well as long-term efficacy and safety there is also major health
economic dynamic between HSCT and standard alternatives in the
main autoimmune disease indications. Although some work has been
performed in MS and type 1 diabetes,53-55 formal health economic
modeling is warranted to fully evaluate the cost-effectiveness of HSCT
vs the standard of care in other diseases.
Should there be “Centers of Excellence” where there is both HSCT
and specialist expertise working closely in the same hospital? The
concept of an experienced team might have benefits not only in
terms of transplant skills, but also familiarity with the clinical
idiosyncrasies within this patient group. Although it is not generally
within the convention and collaborative spirit of the EBMT for
individual center activity and outcome data to be published openly,
such data are routinely available to national professional societies,
health commissioners, and related public health bodies who
oversee the provision of HSCT services in each country. The
association of improved outcomes in more experienced centers
may assist decision-making in commissioning of HSCT in AD on a
national level, with consideration of concentrating activity into
centers of specialization. In addition, the EBMT and JACIE are
currently developing a benchmarking system for center transplant
outcomes across all indications.36
In conclusion, HSCT for AD has evolved gradually on the back of
preclinical experiments, circumstantial data, sporadic treatments, and
small-scale clinical trials to more robust evidence from large database
studies and high-quality randomized controlled trials and other trial
data. “Implementation science” is now needed to bring the field
properly into routine clinical practice alongside alternative treatments
and in tandemwith clinical science, health economics, and education.
Centers of specialization and experience may be required, along with
further refinement of transplant techniques. Ultimately, widespread
clinical adoption between many specialties will be embedded within
appropriately resourced health service delivery.
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